Cite

MLA Citation

    Giulio Metro et al.. “Optimal management of ALK-positive NSCLC progressing on crizotinib.” Lung cancer, vol. 106, 2017, pp. 58–66. http://access.bl.uk/ark:/81055/vdc_100045084215.0x000032
  
Back to record